BIODESIX, INC. Stock Split Ratio
BIODESIX, INC. (BDSX) had Stock Split Ratio of 5.00% as of 2025-09-15, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2026-08-05
- 2025-09-15: Stockholders' Equity Note, Stock Split, Conversion Ratio 5.00%.
- 2020-10-19: Stockholders' Equity Note, Stock Split, Conversion Ratio 16.85%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio |
|---|---|
| 2025-09-15 | 5.00% 10-Q · filed 2026-08-05 |
| 2020-10-19 | 16.85% 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |